Skip to NavigationSkip to content

Novartis provides promising update on Cosentyx in plaque psoriasis

Published on 26/06/19 at 12:24pm

Novartis has revealed brief new data on its IL-17A antibody Cosentyx (secukinumab) in the treatment off plaque psoriasis, showing that the therapy “improves inflammation and rapidly supresses IL-23” in cases of the disease.

Published in the Journal of Allergy and Clinical Immunology, the findings indicated that  Cosentyx generated a “substantial improvement” in inflammation for the majority of patients after as little as 12 weeks by modulating gene expression and reversing plaque histopathology.

Additionally, treatment with the therapy also led to a “rapid and sustained suppression” of additional cytokines, including IL-23 and IL-17F.

“The results of the study highlight the importance of a direct inhibition of IL-17A,” commented Sam Khalil, Worldwide Head of Medical Affairs Immunology, Hepatology and Dermatology at Novartis. “We are excited about this gene expression data which is adding value to the scientific understanding of psoriatic disease. We reimagine science to help improve patients' quality of life.”

Despite these promising findings, the company said that further analysis of clinical, histological and gene transcription changes would be necessary to accurately assess the “full potential” of IL-17A inhibition.

Matt Fellows

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches